Skip to main content
Premium Trial:

Request an Annual Quote

Epitomics Signs Contract to Develop Antibodies for NCI's Proteomics Initiative

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Antibody firm Epitomics today announced it has signed a contract with SAIC-Frederick to develop rabbit monoclonal antibodies in support of the National Cancer Institute's proteomics initiative.

SAIC-Frederick operates under a contract with NCI's Clinical Proteomic Technologies for Cancer program.

Under the terms of Epitomics' contract, the Burlingame, Calif.-based company will develop high affinity and renewable reagents to capture tryptic peptides derived from human plasma protein biomarkers. The peptides will then be used to quantify biomarkers by mass spectrometry-based technologies, such as stable isotope standards and capture by anti-peptide antibodies (SISCAPA) and immuno-matrix-assisted laser desorption/ionization (iMALDI), Epitomics said in a statement.

The firm has completed the first phase of the project to generate and affinity-purify rabbit polyclonal antibodies against the biomarkers. It will now move into the second phase to develop rabbit monoclonal antibodies against selected biomarkers that have been validated.

CPTC is a five-year, $104 million effort to develop new proteomics tools and technologies to accelerate discovery and clinical research. One part of the initiative is to develop better antibodies and reagents for the proteomics community.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.